Joshua Boger - Vertex Pharmaceuticals Insider

Vertex Pharmaceuticals Incorporated -- USA Stock  

USD 158.48  1.07  0.67%

Executive Director and Chairman of Science and Technology Committee

Dr. Joshua S. Boger, Ph.D., is an Independent Director of Vertex Pharmaceuticals Incorporated. Dr. Boger is the founder of Vertex and was a director since our inception in 1989. He was our Chief Executive Officer from 1992 through May 2009. He was our Chairman of our board of directors from 1997 until May 2006 and our President from our inception until December 2000, and from 2005 through February 2009. He was our Chief Scientific Officer from 1989 until May 1992. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology Inflammation and the Department of Biophysical Chemistry
Age: 63  Chairman Since 2009      
617-341-6100  http://www.vrtx.com
Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University.

Joshua Boger Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 10.73 % which means that it generated profit of $10.73 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 5.42 % meaning that it created $5.42 on every $100 dollars invested by stockholders.
The company currently holds 606.43 M in liabilities with Debt to Equity (D/E) ratio of 29.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals Incorporated has Current Ratio of 3.21 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2300 people.Vertex Pharmaceuticals Incorporated (VRTX) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 2,300 people. Vertex Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Vertex Pharmaceuticals Leadership Team

Paul Silva, President
William Young, Director, MBA
David Altshuler, Director
Reshma Kewalramani, President
Jeffrey Chodakewitz, President
Elaine Ullian, Director
Michael Parini, President
Alan Garber, Director, Ph.D
Amit Sachdev, President
Joshua Boger, Chairman
David Greenway, Director
Bruce Sachs, Director, MBA
Margaret McGlynn, Director, MBA
Michael Partridge, President
Yuchun Lee, Director, MBA
Sangeeta Bhatia, Director, Ph.D
Kimberly White, President
Stuart Arbuckle, EVP
Thomas Graney, President, MBA
Terrence Kearney, Director, MBA
Ian Smith, President
Jeffrey Leiden, Chairman, Ph.D

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment
Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorporated. What is your outlook on investing in Vertex Pharmaceuticals Incorporated? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip  Hide

Trending Equities

Currently Active Assets on Macroaxis
RLMD   
 PNK 
Purchased over 100 shares of
few hours ago ago
Traded for 1.6
USAGX   
 NAS 
Purchased over 100 shares of
few hours ago ago
Traded for 13.25
IMMR   
 NMS 
Purchased over 100 shares of
few hours ago ago
Traded for 11.73
NTNX   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 55.15
XENE   
 NGM 
Purchased over 300 shares of
few hours ago ago
Traded for 5.3
ICENX   
 NAS 
Purchased over 100 shares of
few hours ago ago
Traded for 12.46
Also please take a look at World Market Map. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.